| Nature | Inclusion criteria | Patients | Endostar | ICIs | Result | Reference |
---|---|---|---|---|---|---|---|
Lv et.al | clinical | advanced NSCLC with EGFR(-) or ALK(-) and ineffective previous treatment | 34 | 210 mg, continuous intravenous infusion for 168h every 4 weeks | nivolumab (3mg/kg, intravenous drip, day1) every 2 weeks | ORR 41.2%(95%CI:23.7-58.6%) DCR 64.7%(95%CI:47.8–81.6%) CBR 44.1%(95%CI:26.5–61.7%) DOR 6.9m(95%CI:4.4–9.4m) mPFS 6.8m(95%CI: 1.1–12.1) mOS 17.1m (95%CI: 6.6–27.6) grade 1-2 TRAEs 41.1% grade 3-5 TRAEs 11.8% | [19] |
Wu et.al | clinical | advanced NSCLC | 21 | usage not mentioned | Camrelizumab | ORR 71%, DCR 100% thrombocyto-penia 24%,>3 grade 10% nausea and vomiting 24%,>3grade 5% liver damage 19% RCCEP related with camrelizumab>3 grade 0% | [17] |
Wu et.al | clinical | advanced stage (IIIB and IV) NSCLC | 27 | 210 mg, continuous intravenous infusion from day 1-3 every 3 weeks | Camrelizumab 200 mg every 3 weeks | ORR 48%, DCR 85%,CR 3.7% mPFS 8.9m anemia67%,>3 grade 11% nausea and vomiting 41%, >3 grade 4% immune-related hepatitis 3.7% RCCEP related with camrelizumab 41% | [18] |